KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Karin Burock, Maanasa Gowda, Tommaso Stefanelli, Stephanie J Lee, Takanori Teshima, Franco Locatelli

J Clin Oncol 43(23) 2566-2571

PMID40561385
PMCIDPMC12316163
DOI10.1200/JCO-24-02477
发表日期2025-06-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIG 1.:森林图/亚组分析图;FIG 2.:非 KM 图。
摘要

摘要

In REACH3 (ClinicalTrials.gov identifier: NCT03112603), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.Kaplan-Meier analysis of (A) FFS and (B) DOR in the full analysis set. FFS is a composite end point that includes relapse/recurrence of underlying disease or death due to underlying disease, nonrelapse mortality, or addition/initiation of another systemic therapy for cGVHD. DOR is defined as the first response until progression, death, or the date of additional systemic therapies. BAT, best available therapy; cGVHD, chronic graft-versus-host disease; DOR; duration of response; FFS, failure-free survival; HR, hazard ratio; NE, not estimable (not reached).
非 KM Figure
FIG 2.(A) ORR at week 24 and (B) BOR up to week 24 of the crossover period in the crossover population and in the primary analysis population at week 24 of the primary treatment period for REACH3. a ORR was the primary end point and BOR was a key secondary end point in the primary analysis of the REACH3 at week 24. 2 BAT, best available therapy; BOR, best overall response; CR, complete response; ORR, overall response rate; PR, partial response.
非 KM Figure